Developing as a promising development in the struggle against obesity, Retatrutide is generating considerable interest . It combines effects of two recognized GLP-1 binding agonists, semaglutide , plus an additional glucose-dependent peptide component. Early clinical data have demonstrated significant fat loss in patients with a high BMI , perhaps